Most decisions in regulated biomedicine do not fail. They drift.

Not because the science was wrong.
Not because the strategy was flawed.

​

But because the moment a decision needed to become binding, truly owned, defensible and irreversible, the conditions for that were not in place.

​

What organisations experience as delay, friction or misalignment is often something deeper.

 

A structural failure in how decisions are formed.

​

THE PROBLEM

Decisions tend to break much earlier than people think.

They fracture at the point where evidence, accountability and commercial logic first begin to separate.

 

By the time that separation becomes visible, the options are already narrowing.

 

The problems that appear later such as regulatory friction, stalled adoption or commercial hesitation are usually the invoice for decisions that were never structurally sound.

 

I try to work before that invoice arrives.

This pattern appears across therapeutic strategy, regulatory judgement, evidence translation, access design and commercial decision making.

​

The context changes.
The pressure changes.

​

The architecture problem rarely does.

​

​​​​​​​​​​​​​​​​WHERE DECISIONS BREAK

​Across regulated biomedicine the pattern is surprisingly consistent.

​

Evidence is interpreted differently across functions.
Accountability remains diffuse.

Commitments harden before their consequences are fully understood.

​

Organisations then attempt to resolve this through more analysis, more alignment and more process.

 

But the difficulty is rarely analytical.

It is structural.

​

Antimicrobial resistance makes this particularly visible. Scientific urgency is widely recognised, yet durable market commitment remains fragile.

 

The same structural tension appears elsewhere whenever evidence is complex, incentives are misaligned and decisions cannot easily be reversed.

 

WHAT I FOCUS ON

Not optimisation. Not execution. Decision integrity.

The question is whether the decision being made is actually the decision people believe they are making, and whether it will hold once it becomes irreversible.

 

Common fracture points include:

• Evidence quietly turning into value judgements that no one has fully examined

• Access and adoption assumptions separating from reality

• Economic logic weakening when action finally has to be taken

• Governance being deferred rather than embedded

• Accountability spreading across functions while commitments continue to solidify

 

The objective is not certainty.

​

It is coherence. Decisions whose consequences are understood, owned and defensible before they become irreversible.

​

TYPICAL SITUATIONS

Situations where evidence is no longer the main problem, yet the decision still refuses to close.

 

Examples include moments when:

• governance and accountability are misaligned across functions

• commercial logic and institutional logic have quietly diverged

• a decision is becoming irreversible without a clear owner

• structural commitments will not hold under regulatory or market pressure

• further analysis or alignment will not resolve the underlying issue

 

These moments often appear late.

 

QUESTIONS I WORK ON

Most organisations do not struggle because they lack analysis.

​

They struggle because certain decisions cannot easily be closed.

​

The situations where I am usually involved tend to begin with questions such as:

• What decision are we actually trying to make, and who ultimately owns it?

• If the evidence is strong, why is the organisation still unable to commit?

• Which assumptions in this strategy would fail first under regulatory, commercial or reputational pressure?

• Where has accountability quietly separated from the consequences of the decision?

• Are we trying to optimise execution when the real problem is structural?

• Are we analysing uncertainty, or avoiding the moment the decision becomes binding?

​

These questions appear across therapeutic strategy, regulatory judgement, market access, investment decisions and health system governance.

​

The details change.

The underlying architecture rarely does.

​

In reality the structural cause usually sits much earlier.

​

CONTEXT

This perspective was shaped inside global biomedical organisations where scientific evidence, regulatory scrutiny, commercial consequences and institutional accountability meet.

 

In those environments decisions cannot remain theoretical for long.

 

They eventually have to become binding, often under intense regulatory, financial and reputational pressure.

 

Working repeatedly at that boundary reveals the same pattern.

 

The difficulty is rarely the analysis.

 

The real question is whether the structure around the decision will hold once the consequences arrive.

 

For professional background and selected work, see LinkedIn.

​

CONVERSATION

If you are approaching a decision that cannot be resolved simply through more analysis, more alignment or more process, and where the consequences will extend well beyond the meeting in which it is made, I am open to a conversation.

​

Contact me using harpal.dhillon@protonmail.com or Explore and Connect on LinkedIn